Australia's Somnomed rises on strong revenue growth
26/07/2022 04:10
** Shares of Somnomed Ltd SOM.AX rise as much as 10.4% to
A$1.325, their highest since June 9
** Co, which provides treatment solutions for sleep-related
breathing disorders, posts Q4 revenue of A$21.3 mln ($14.85
mln), up 32% on pcp urn:newsml:reuters.com:*:nASX9T4v5R
** Co maintains FY22 guidance of breakeven EBITDA
** Shares mark their biggest intraday pct gain since March
21
** As of last close, stock down 48.9% this year
($1 = 1.4339 Australian dollars)
(Reporting by Himanshi Akhand in Bengaluru)
((Himanshi.Akhand@thomsonreuters.com;))
Recent news on SomnoMed
See all newsAustralia's Somnomed jumps most in 7 months on strong half-year earnings
Brief: Somnomed® Increases Investment In Managed Care Infrastructure
Australia's Somnomed hits 32-month high on upbeat revenue growth
Brief: Somnomed Says Q1 FY26 Revenue Up 13.5% To A$28.7 Million
Brief: Somnomed Says FY EBITDA AUD 9.2 Million